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Abstract
Abnormal genome hypermethylation participates in the tumorigenesis and development of prostate cancer. Prostate
cancer cells highly express DNA methyltransferase 3 (DMNT3) family genes, essential for maintaining genome
methylation. In the present study, multi-target siRNA, based on the homologous region of the DNMT3 family, was de-
signed for the in vitro investigation of its effects on the proliferation, migration, and invasion of TSU-PR1 prostate
cancer cells. The consequential cell-cycle derangement, through DNMT3A/B or only DNMT3B silencing, was par-
tially efficient, without affecting apoptosis. DNMT3A silencing had absolutely no effect on changing TSU-PR1 cell bi-
ological behavior. Hence, DNMT3B alone apparently plays a key role in maintaining the unfavorable behavior of
prostate-cancer cells, thereby implying its potential significance as a promising therapeutic target, with DNMT3A
simply in the role of helper.
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Introduction
Prostate cancer is the most common solid tumors in
men in developed countries. In China prevalence is contin-
uously on the rise, due to changes in lifestyle and an aging
population. Abnormal regulation of the enzymes involved
in DNA methylation, and incorrect methylation of CpG is-
lands, are all common phenomena in human tumors (Shar-
ma et al., 2010). Specifically, abnormal genome hyper-
methylation in the tumorigenesis and development of
prostate cancer, with higher expression of DNMT proteins
compared to normal prostate tissue, has been established
(Benbrahim-Tallaa et al., 2007; Morey Kinney et al., 2008;
Lin et al., 2011). The DNMT family, including DNMT1,
DNMT2, DNMT3, etc., plays a critical role in the initiation
and maintenance of DNA methylation. The DNMT3
subfamilyincludesDNMT3AandDNMT3B,crucialinthe
process of de novo genome methylation (Das and Singal,
2004; Siedlecki and Zielenkiewicz, 2006; Patra et al.,
2008). The catalytic domain of DNMT3 resides in its C ter-
minal, which is highly conserved among mammals (Cheng
and Blumenthal, 2008). As the specific function of the
DNMT3 subfamily in the initiation and development of
prostate cancer remains elusive, it was decided to apply
novel multi-target small interfering RNA (siRNA) target-
ing at the conservative region of human DNMT3 family
proteins to the human prostate cancer cell line TSU-PR1,
andthenrecordandanalyzesubsequentchangesinbiologi-
cal behavior. The results could be of help in enlightening
the roles played by the observed high-level DNMT expres-
sion in prostate cancer cells. Furthermore, our Multi-target
siRNA design will also be useful in discerning the impor-
tance of the two subfamily members.
Material and Methods
Multi-target siRNA construction
The homologous sequences of DNMT3A
(NM175629.1NM022552.3NM175630.1) and DNMT3B
(NM066892NM175848.1NM175849.1NM001207055.1N
M00120756.1) genes were determined through 2 Se-
quence-Blast. Three pairs of siRNAs (siDNMT3AB-1,
siDNMT3AB-2 and siDNMT3AB-3) for targeting at the
conservative sequence coding catalytic domain of both
DNMT3A and DNMT3B were designed online at the
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Research Articlewebsite of Ambion Inc. The principals, as presented in Ta-
ble 1, were strictly observed for siRNA optimization.
siRNA-NC served as negative control (5’-GACTTCATA
AGGCGCATGCTTCAAGACGGCATGCGCCTTATGA-
3’) The sequences of siRNA for DNMT3A and DNMT3B
were taken from a previous study (Robert et al., 2003:
DNMT3A 5’- GCCTCAGAGCTATTACCCA-3’,
DNMT3B 5’- GAAGATCAAGCTCGCGACT-3’). After
careful checking to assure specificity across the whole ge-
nome, all the siRNAs, were synthesized by Wuhan Genesil
Biotechnology Co., Ltd. A FAM – labeled siRNA was also
synthesized to evaluate transfection efficiency.
Cell line screening
Human prostate cancer cell LNCaP and its sublines
(C4,C42,C4-2B),ARCaPcelllinesIA-8,IF-11,andPC-3,
DU-145, TSU-PR1 were provided by Professor Leland
WK Chuang (Emory University, USA), and preserved at
the Institute of Urology, Medicine College of Xi’an
Jiaotong University.
Total RNA was isolated with Trizol and quantitated
by absorbance at 260 nm. 2 g RNA was reverse-trans-
cribed into cDNA by using a RevertAidtm First Strand
cDNA Synthesis Kit (MBI Fermentas, St Leon-Rot, Ger-
many). Primer sequences for DNMT3A, DNMT3B and
-actin are presented in Table 2. The PCR amplification
procedure was as follows: 94 °C for 5 min, 32 cycles of
90 °C for 30 s, 58 °C for 30 s, 72 °C for 45 s, followed by a
final extension of 72 °C for 7 min. PCR products were run
on a 2% agarose gel (120 V, 45 min) and visualized using
ethidium bromide staining (Benbrahim-Tallaa et al.). The
mean density of each band was analyzed using Glyko
BandScan software (Glyko, Novato, USA).
All the cells were washed twice with PBS (0.01 M,
pH 7.4), and then lysed by an ice-cold radio immuno-
precipitation assay RIPA buffer (Beyotime Institute of bio-
technology, China) containing 1% Cocktail and 1 mmol/L
PhenylmethanesulfonylfluoridePMSF(BeyotimeInstitute
of biotechnology, China). Purified lysates (150 g) of each
sample were separated by 12% SDS-PAGE and transferred
to a nitrocellulose membrane at 4 °C (25 V, 12 h). The
membrane was incubated with TBST (50 mM Tris,
150 mM NaCl, 0.05% Tween 20, pH 7.6)-diluted primary
antibodies against desired molecules (Santa Cruz, CA,
USA) overnight at 4 °C, and then incubated with HRP cou-
pled rabbit anti-goat IgG (1:3000) or mouse IgG (1:3000)
(Invitrogen, Life Technologies Corporation, USA) for 1 h
atroomtemperature.Finally,themembranewasvisualized
by ECL (Beyotime Institute of biotechnology, China).
Loading difference was normalized using a human
GAPDH antibody (Invitrogen, Life Technologies Corpora-
tion, USA). The mean density of each band was analyzed
using Glyko BandScan software (Glyko, Novato, USA).
Transfection
The optimal transfection concentration was deter-
mined by siRNA-FCM. The cell line which expressed
DNMT3A and DNMT3B at the highest level was
transfected with siDNMT3AB-1, siDNMT3AB-2,
siDNMT3AB-3 and siRNA-NC respectively, according to
the standard lipofectamintm 2000 protocol (Invitrogen,
CA, USA). The culture medium was replaced by fresh
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Table 1 - Location of candidate siRNA target sequences in different DNMT3A and DNMT3B transcripts.
DNMT3AB-1 DNMT3AB-2 DNMT3AB-3
Accession No. 5’-CCAGTGATGATTGATGCCA-3’ 5’-GATACTTCTGGGGCAACCT-3’ 5’-ATAAACTCGAGCTGCAGGA-3’
NM175629.1 2670-2685(EXON 23) 2715-2731(EXON 23) 2778-2788(EXON 24)
DNMT3A NM022552.3 2589-2604(EXON 23) 2634-2650(EXON 23) 2697-2707(EXON 24)
NM175630.1 No similarity 814-821(EXON 5b) 1177-1185(EXON 5b)
NM066892 2473-2491(EXON 21) 2519-2537(EXON 21) 2576-2594(EXON 22)
NM175848.1 2413-2431(EXON 21) 2459-2477(EXON 86) 2516-2534(EXON 22)
DNMT3B NM175849.1 2413-2431(EXON 21) 2459-2477(EXON 21) 398-405(EXON 3)
NM001207055.1 2287-2305(EXON 21) 2333-2351(EXON 21) 398-405(EXON 3)
NM00120756.1 2185-2203(EXON 21) 2231-2249(EXON 21) 398-405(EXON 3)
Table 2 - Primer sequences for DNMT3A, DNMT3B and -actin.
Primer Sense (5’-3’) Antisense (5’-3’) Product length (bp)
DNMT3A CACACAGAAGCATATCCAGGAGTG AGTGGACTGGGAAACCAAATACCC 551
DNMT3B AATGTGAATCCAGCCAGGAAAGGC ACTGGATTACACTCCAGGAACCGT 190
-actin ATCATGTTTGAGACCTTCAACA CATCTCTTGCTCGAAGTCCA 330DMEM (Gibco, Life Technologies Corporation, United
States) supplemented with 10% fetal bovine serum (FBS) 4
h after the transfection process. Total RNA and proteins




lium bromide (MTT, Sigma, St Louis, MO, USA) prolifer-
ationassayswereperformedtoassesschangesinTSU-PR1
cell viability after transfection. After the respective trans-
fection process of siDNMT3AB-1 (Group 1), siDNMT3B
(Group 2), siDNMT3A (Group 3) and siRNA-NC (Nega-
tive Control) for 48 h, cells were seeded at a density of 1 x
10
3/wellin96-wellplates.Afterculturefor24h,48h,72h
and 96 h, 20 L of MTT (5 mg/mL in PBS) was added to
each well, and kept for 4 h, whereupon the medium was re-
moved and 150 L DMSO added to solubilize formazan
crystals. Absorbance (OD) was measured at 590 nm by a
Microplate Autoreader (Bio-Tek Instruments, VT, USA).
The growth inhibitory rate was calculated according to the
formula: growth inhibitory rate = (average OD value in the
control group - average OD value in the treatment
group)/average OD value in the control groupx100%.
Scratch assay
Cells from each group were inoculated into 6-well
dishes at a concentration of5x1 0
4/ well at 48 h after
transfection.Whencellularfusionreached80%,a20Ltip
was used to draw a vertical line across the dishes, after
which cell debris was washed twice with sterile PBS, and
fresh medium added. Photos were taken immediately after
scratching, as well as 24 and 48 h later. Wound closure was
monitored with a UOP DSZ500X inverted microscope
(UOP Microscope, Chongqing, China). Wound sizes were
checkedagainstthescaleoftheimagestoensurethatallthe
respective widths were the same at the start. Migration in-
hibitory rate was calculated according to the formula: mi-
gration inhibitory rate = (average migration distance in the
control group – average migration distance in the treatment
group)/average migration distance in the control
group x 100.
Invasive assay
Matrigel (Sigma, St Louis, MO, USA) and serum-
free RPMI-1640 medium (Gibco, Life Technologies Cor-
poration, USA) were mixed at a ratio of 1:5. 50 Lo ft h e
mixture was placed into the upper chamber of a Transwell
permeable support (Corning, NY, USA) with an 8 m pore
size,priortoincubatingat37°Cfor4h.100Lsuspension
of each group, containing5x1 0
3 transfected cells were in-
oculated into the upper chamber of the Transwell perme-





The number of penetrated cells was counted in three ran-
dom fields (100x) per filter.
Cell cycle apoptosis assay
48 h after transfection, the TSU-PR1 cells of each
group were collected and labeled with propidium iodide
(Sigma, St Louis, MO, USA). 1 x 10
4 cells per group were
counted by flow cytometry (FACSCalibur, BD Inc, USA)
to determine both changes in DNA content throughout the
cell-cycle, and the percentage of cells in each cell stage.
Cell-cycle regulatory protein Cyclin D and PCNA were
tested by western blotting using multiclonal human Cyclin
D (1:500) and PCNA (1:300) antibodies (Santa Cruz, CA,
USA), respectively.
Apoptosis assay
48 h after transfection, TSU-PR1 cells of each group
were collected and labeled with Annexin V Kit (Sigma, St
Louis,MO,USA).FlowcytometrywasusedtodetectFITC
and propidium iodide fluorescence of each group. The
number of apoptotic cells was also calculated. Apoptosis
regulatory protein Cleaved Caspase 3 was tested by west-
ern blotting using polyclonal human Caspase 3 (1:500)
(Santa Cruz, CA, USA).
Statistical analysis
All assaying was three-fold. Data were presented as
means  SEM. One-way ANOVA was applied for multiple
comparisons between groups. In all cases, p < 0.05 was
considered statistically significant. All statistical analyses
were performed using SPSS 13.0 (SPSS Inc, Chicago, IL,
USA).
Results
DNMT3A and DNMT3B expression in prostate
cancer cell-lines
Compared with negative control BPH cells, all pros-
tate cancer cell lines expressed DNMT3A and DNMT3B at
much higher levels (Figure 1). As revealed by semi-quan-
tative PCR and western blot analysis, TSU-PR1 and IA-8
were the two cell lines which showed the the highest levels
of DNMT3A and DNMT3B expression. Since IA-8 trans-
fection efficiency was extremely low, TSU-PR1 entered
into subsequent studies.
Inhibition efficiency
As determined by siRNA-FCM, the optimal trans-
fection concentration was 140 nM. In comparison with the
negative control, siDNMTAB-1 could effectively knock
down both DNMT3A and DNMT3B, whereas
siDNMTAB-2 only inhibited DNMT3B expression, and
166 Multi-target siRNA against DNMT3A/B in prostate cancersiDNMT3AB-3 had absolutely no effect on the expression
of either (Figure 2).
Efffects of siRNA transfection
MTT assaying indicated that the knockdown of
DNMT3A/B (Group1) or DNMT3B alone (Group 2) sig-
nificantly inhibited the proliferation of TSU-PR1 cells at
72 h (p < 0.05), whereas silencing DNMT3A (Group 3)
alone had no inhibitory effect on the growth of TSU-PR1
cells compared to the negative control (p > 0.05) (Figu-
re 3A).
Migration inhibition rates of Groups 1, 2 and 3 were
10.1  1.25%, 9.87  0.99% and 11.67  0.89% respec-
tively, at 24 h after transfection, with no significant differ-
enceamongthethree.At48hpost-transfection,theratesof
Group 1, Group 2 and Group 3 were 43.2  1.58%,
39.74  0.72% and 14.11  0.52%, respectively; hence, in-
hibition in Groups 1 and 2 was significantly lower than in
Group 3 (p < 0.05) (Figure 3B).
According to invasive assaying, the number of TSU-
PR1 cells penetrating the membrane in Groups 1 and 2 was
significantly lower (p < 0.05) than in Group 3 and negative
control, with no significant difference between the former
two (Figure 3C, D).




noted between Groups 1 and 2 (Figure 4A,B).
In Groups 1, 2 and 3 and negative control, the early
apoptosis rates were 0.81  0.12%, 0.55  0.11%,
1.59  0.19% and 0.62  0.12%, respectively, and the late
apoptosisrates 9.46  0.31%, 4.89  0.22%, 4.49  0.45%
and6.960.35%(Figure4C).Therewasnosignificantdif-
ference in either of the two rates among the experimental
groups.
In western blot analysis (Figure 4D), whereas cyclin-
D and PCNA expression in Groups 1 and 2 decreased sig-
nificantly, cleaved caspase3 was not detected in either
group. Consistent with the results of cell cycle and apop-
tosis analyses, there was no significant change in the ex-
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Figure 1 - DNMT3A and DNMT3B expression in prostate cancer cell
lines assayed by semi-quantative PCR (A) and western blotting (B). The
Hela cell line served as positive control and the BPH as negative.
Figure 2 - DNMT3A and DNMT3B expression in TSU-PR1 cells after
siRNA transfection detected by western blot analysis.Takada et al., 2010). DNMT expression is also elevated in
many cancer tissues (Girault et al., 2003; Auerkari, 2006;
Kanai and Hirohashi, 2007; Ding et al., 2008). High
DNMT expression, which generally takes place prior to
DNA methylation, might possibly be one of the causes of
abnormal DNA methylation. Besides the role played by the
DNMT family in DNA hypermethylation and tumorige-
nesis, supression of DNMT1 expression in bladder cancer
cells was shown to induce demethylation and reactivation
of the silenced tumor suppressor gene CDKN2A. On the
other hand, the colon cancer cell HCT116 lacking DNMT1
expression still presented significant DNA methylation,
168 Multi-target siRNA against DNMT3A/B in prostate cancer
Figure 3 - Results from proliferation (A), migration (B) and invasion (C, D) assays of TSU-PR1 cells after siRNA transfection. Scale bar = 200 m.whereas HCT116 clones with inactivation of both DNMT1
and DNMT3B showed much lower levels of DNA methy-
lation (Robert et al., 2003), thereby indicating that mem-
bers of the DNMT family work together complementarily
or synergistically in the control of tumorigenesis,
Based on these findings, the community has come to
consider DNMT as a new target for tumor treatment. 5-aza
-2’-deoxycytidine (5-Aza-CdR, Decitabine), a DNMT in-
hibitor, is capable of suppressing tumor cells (Momparler,
2003, 2005) by combining with DNMT genes in the pro-
cess of promoter methylation (Momparler, 2003, 2005; Yu
and Wang, 2008). However, its short half-life in vivo, fre-
quent inactivation caused by cytidine deaminase, neutro-
penia, and certain other side effects, have all limited its
application in the case of solid cancers, whereby the urgent
need for finding a new way of improving the stability and
efficiency of these inhibitors.
In recent years, small interfering RNA (siRNA) tech-
nology has reached maturity, and is now widely used in
cancer research in the characterization of gene functions
(Hannon,2002;Paietal.,2006).Thetraditionaldesignpat-
tern is that one piece of siRNA aims at one specific se-
quence (Reynolds et al., 2004). Given that tumorigenesis
anddevelopmentgenerallyinvolvedysfunctionofavariety
of co-regulated genes, silencing a single gene often does
not necessarily lead to the expected results. The
simultaneous knockdown of multiple genes can be
achieved by either co-transfection (Leu et al., 2003) or du-
plication of transfection (Przybylski et al., 2010). How-
ever, the drawbacks are also obvious. Experimental steps
are complicated, and excessive transfection reagents, by
impairing target cells, may finally lead to false positive re-
sults.Incontrast,multi-targetsiRNAiscapable,notonlyof
knocking down several genes simultaneously, with much
less side effects than traditional methods. Kunze et al.
(2008) when inhibiting the expression of the apoptosis sup-
pressor protein bcl-2 family in bladder cancer cells using
multi-target siRNA, showed that the proliferation of cancer
cells was significantly suppressed. In the present study, the
successfulconstructionofmulti-targetsiRNAaimingatthe
DNMT3 family proved its biological validity.
In-depth analysis indicated the C terminal enzyme
catalytic region of the DNMT3 family to be highly con-
served and homologous. The strong point of the present
study was the successful synthesis of multi-target siRNAs
targeting DNMT3A and DNMT3B simultaneously. Nota-
bly, silencing of the DNMT family could dramatically sup-
presstheproliferation,invasionandmigrationofTSU-PR1
prostate cancer cells. Obviously, cell-cycle related protein
expressionalsochanged.Theobservedbiologicaleffectsof
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Figure 4 - Cell cycle distribution (A, B and C) and apoptosis changes (D) in TSU-PRI cells after siRNA transfection.suppression of DNMT3 expression may be due to the ge-
nome methylation level being down-regulated by silencing
of the DNMT3 family, and thus, the genes which had been
suppressed through abnormal hypermethylation in cancer
cells regained activity. The present findings imply that the
DNMT3 family may be a promising therapeutic target.
Unexpectedly, the apoptosis level of TSU-PR1 cells
was not significantly influenced by silencing of the
DNMT3 family, most possibly for two reasons. In the first
place,cell-speciesspecificitymightinfluencetheapoptosis
procedure. For example, it was reported that p53 was nec-
essary for DNMT to induce cell apoptosis (Schneider-
Stock et al., 2005), whereas TSU-PR1 cells did not express
p53 (Wang et al., 2009). Secondly, cell-cycle related regu-
lators, such as the DNA repair system and anti-apoptosis
genes might be activated by DNMT3 silencing, thereby
preventing apoptosis of TSU-PR1 cells.
To further elucidate the function of the DNMT3 fam-
ily, we separately silenced DNMT3A/B, DNMT3A and
DNMT3B. Although DNMT3A/B or DNMT3B silencing
significantly inhibited TSU-PR1 cell proliferation, inva-
sionandmigration,withnosignificantdifferencesbetween
the two, DNMT3A silencing lead to no observable chan-
ges. On the other hand, proliferation and apoptosis related
proteinsdidpresentconsistentchanges.Thesilencingofei-
ther DNMT3A/B or DNMT3B expression significantly re-
duced the expression levels of cyclinD1 and PCNA,
whereas no significant changes were manifest after
DNMT3AsilencinginTSU-PR1cells.Similarresultswere
reported in liver cancer cells following DNMT3B knock-
down (Bai et al., 2005). According to flow cytometry,
apoptosis-related protein caspase3 was not detected in any
group. Therefore, although abnormal DNMT3 expression
in TSU-PR1 prostate cancer cells regulated the cell cycle
via cyclin D1, cell apoptosis was not visibly affected. Fur-
thermore, DNMT3B appeared to play an overwhelming
role in the process, whereas DNMT3A simply functioned
as assistant, thereby presupposing that the spontaneous
knocking down of both DNMT3A and DNMT3B together
wasinnowaymoreadvantageousthanknockingdownjust
DNMT3B.
This is a first-time elaboration of DNMT3-family
functions in prostate cancer. However, due to the limited
period and low efficiency of transient transfection, the ef-
fect of DNMT3 family silencing requires further valida-
tion. The establishment of a stable and efficient knock-out
oftheDNMT3familyinprostatecancercellswillbethefo-
cus of our future work.
In conclusion, we first demonstrated that multi-target
siRNA targeting at the conservative homology region of
DNMT3 family members, could effectively inhibit the pro-
liferation, migration and invasion of TSU-PR1 prostate
cancer cells. This study has thus laid the foundations for
further research on the important role of DNMT3 in pros-
tatecancercells,andprovidesmomentumtotheclinicalap-
plication of multi-target siRNA against DNMT3A and
DNMT3B in the treatment of prostate cancer.
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